
Axcelead Drug Discovery Partners株式会社
Japan axcelead.com From their website, Nov 2026
Work here? Claim this listing
About
Axcelead Drug Discovery Partners株式会社 is a drug discovery partner that supports pharmaceutical companies, biotech firms, and academic researchers. It provides integrated discovery services in Japan, covering target validation, hit finding, lead optimization, nonclinical development, and related biology, chemistry, pharmacology, and ADMET work.
Axcelead Drug Discovery Partners株式会社 is a CRDMO in Japan, founded in 2017. It lists 16 services, including Project co-creation solution, Kinase platform and Drug repositioning.
Services
Project co-creation solution
Works with clients through discussion and shared problem-solving across target identification, hit finding, lead creation, lead optimization, candidate selection, and nonclinical development.
Kinase platform
Provides kinase-focused discovery tools, including focused libraries, kinase panel data, and selective tool compounds to accelerate early kinase drug discovery.
Drug repositioning
Uses public databases and fingerprinting data to identify candidate indications for existing, developing, or discontinued compounds and supports target validation.
Genetically modified mouse and rat generation
Creates and breeds KO and KI mice and rats using ES cell homologous recombination and CRISPR/Cas9, with downstream phenotypic and pharmacology/pathology evaluation.
Omics
Performs multi-omics analyses for mechanism exploration, biomarker discovery, bioinformatics, single-cell and single-nucleus analysis, and spatial transcriptomics.
Pathology and biochemistry
Supports pathology peer review, image-based efficacy evaluation, laser microdissection, and assays for liver and kidney injury and miRNA analysis.
Screening
Manages compound libraries and conducts HTS, HT-ASMS, phenotype-based screening, and iPS cell-based compound screening.
Chemistry
Provides medicinal chemistry, computational chemistry, parallel synthesis, analytical chemistry, synthetic chemistry, and flow chemistry.
8 more services
- Pharmacokinetics
- Safety
- Support for cancer-related drug discovery
- Support for immune disease-related drug discovery
- Evaluation related to neurological and muscular diseases
- Support for kidney disease-related drug discovery
- Support for metabolic disease-related drug discovery
- Support for cardiovascular disease-related drug discovery
- Turnaround
- 3 months to 12 months
- What to send
- Gene names you are interested in
- Drug discovery target information for compounds you have on hand
How to order from Axcelead Drug Discovery Partners株式会社
What to send, as they list it: Gene names you are interested in; Drug discovery target information for compounds you have on hand. Turnaround they state: 3 months to 12 months. They take requests through the contact form on their website. You can contact them directly from this page, or request a quote through Midgard.
Capabilities
- Assays and studies
- HTS
- In vivo
- PK/PD
- ADME
- ADCs
- HPLC
11 more
- HT-ASMS
- TR-FRET kinase panel assay
- In vitro assay
- In vivo assay
- ADMET screening
- hERG assay
- Single-cell analysis
- Single-nucleus analysis
- PK/PD analysis
- EC50/IC50 measurement
- ADCC activity assay
- Scale and capacity
- Over 1,500,000 compounds library
- Kinase Focused Library of about 5,000 compounds
- Over 20 homo KO mice and rats in about 3 months
- More than 50 Homo KO/KI mice in about half a year from 1 male KO/KI mouse
- KI mice of up to 40 kbp
- KI mice of up to 17 kbp
Instruments and platforms
- IVIS
- HPLC
- Chiral HPLC
- NMR
- Syncropatch
Modalities and species
- Modalities
- ADC
- Oligonucleotide
- mRNA
- Gene editing
- Species and models
- Rat
- KO rat
- KI rat
- Xenograft model
- PDx model
- Syngeneic model
Certifications
As the company states them, with the certificate or registry record where there is one.
GLPSelf-reported
Details
- Type
- CRDMO
- Founded
- 2017
- Quality
- BSL2 (HTS) · IND・NDA (Testing and submission support)
- Based in
- Japan
Public records
- Biocom California CRO directory
- Candidate Generation, drug discovery, High Throughput Screening, IND enabling studies, Non-clinical pharmacology/DMPK/safety studies source